B

대봉엘에스

078140KOSDAQ의약품 제조업

63.5 / 100

Reference Date: 2026-04-13

Financial Score25.5 / 40
News Sentiment20.0 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly down 2.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Daebong LS, established in 1986, operates across medical beauty and bio sectors, developing safe and effective products aligned with its mission to provide solutions for a healthier, more beautiful life. Key offerings include respiratory treatments, hypertension drugs, and functional cosmetic materials, with consolidated revenue reaching 1,021 billion KRW in 2025, reflecting an 8.6% year-over-year growth.

Number of Employees

138people

Average Salary

54.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
11.02Industry Average 14.806.5Point

Lower than industry avg (good)

PBR
0.64Industry Average 1.045.5Point

Lower than industry avg (good)

ROE
7.05Industry Average 4.425.5Point

1.6x industry avg (good)

Debt Ratio
39.82Industry Average 11.980.0Point

3.3x industry avg (risky)

Trend 2023~20258.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲7.9% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲59.6% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 5.8% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 3Neutral 0Negative 0Average Sentiment Score 80

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 10,130Won52-week high 14,89052-week low 9,560
1-month return2.0Point

1m -2.13% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral정기주주총회결과2026-03-31
  • Neutral감사보고서제출2026-03-23
  • Neutral사업보고서 (2025.12)2026-03-23
  • Neutral[기재정정]사업보고서 (2025.12)2026-03-23
  • Neutral주주총회소집공고2026-03-16